Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07454850 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableStart date: Aug 30, 2026 to Oct 30, 2026Primary and study completion pushed from Oct 16, 2026 to Mar 30, 2027 · Secondary endpoints: details revised at 6 of 26 entries · Eligibility criteria expanded, about 3 wordsShow 3 more changesShow less
Primary and study completion pushed from Oct 16, 2026 to Mar 30, 2027
Secondary endpoints: details revised at 6 of 26 entries
Eligibility criteria expanded, about 3 words
MinorRe-verified, no change to tracked fieldsv5
NotableStart date: Jun 16, 2026 to Aug 30, 2026Primary and study completion dates: Oct 19, 2026 to Oct 16, 2026v4Show 1 more changeShow less
Primary and study completion dates: Oct 19, 2026 to Oct 16, 2026
NotableStart date: May 16, 2026 to Jun 16, 2026Primary and study completion pushed from Sep 19, 2026 to Oct 19, 2026v3Show 1 more changeShow less
Primary and study completion pushed from Sep 19, 2026 to Oct 19, 2026
NotableStart date: Mar 17, 2026 to May 16, 2026v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to assess demographics, clinical features, treatment patterns, and the comorbidity burden and its impact on CML patients in the real-world clinical setting in Kuwait. Adult patients with Philadelphia positive-chromosome (Ph+ve) CML who have received at least one line of tyrosine kinase inhibitor (TKI) treatment, such as but not limited to imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib will be included. The study will use data from the hospital records of CML patients between January 2014 and January 2024.